• Patients with histologically confirmed advanced solid tumors (regimen A), breast or pancreas (regimen B), or gastric cancer (regimen C)

• Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy

• Prior treatment with protein-bound paclitaxel allowed if it has been six months since received or progressed on protein-bound paclitaxel and plan to continue to receive protein-bound paclitaxel with MinnelideTM Capsules

• One or more metastatic tumors measurable per RECIST v1.1 Criteria

• Karnofsky performance ≥ 70%

• Life expectancy of at least 3 months

• Age ≥ 18 years

• Signed, written IRB-approved informed consent

• A negative pregnancy test (if female)

• Acceptable liver function:

‣ Bilirubin ≤ 1.5 times upper limit of normal

⁃ AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2.5 times upper limit of normal (if liver metastases are present, then ≤ 5 x ULN is allowed)

⁃ Albumin ≥ 3.0 g/dL

• Acceptable renal function:

• o Serum creatinine within normal limits, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

• Acceptable hematologic status:

‣ Granulocyte ≥ 1500 cells/mm3

⁃ Platelet count ≥ 100,000 (plt/mm3)

⁃ Hemoglobin ≥ 9 g/dL

• Urinalysis:

• o No clinically significant abnormalities

• Acceptable coagulation status:

‣ PT ≤ 1.5 times institutional ULN

⁃ PTT ≤ 1.5 times institutional ULN

• For men and women of child-producing potential, the use of effective contraceptive methods during the study